ArticleNature medicine2023

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.

Kelly C Goldsmith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.